Oncology Institute (DFPH) Net Income towards Common Stockholders (2020 - 2026)

Oncology Institute (DFPH) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 86.97% year-over-year to -$2.1 million; the trailing twelve-month figure through Mar 2026 stood at -$36.3 million (up 31.29% YoY), and the FY2025 full-year result was -$50.3 million, up 5.09% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$2.1 million, up from -$6.4 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $19.3 million in Q1 2022 and bottomed at -$30.0 million in Q1 2023.
• The 5-year median for Net Income towards Common Stockholders is -$13.2 million (2024), against an average of -$11.3 million.
• Peak annual rise in Net Income towards Common Stockholders reached 238.35% in 2022, while the deepest fall reached 673.67% in 2022.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$11.0 million in 2022, then tumbled by 70.38% to -$18.8 million in 2023, then surged by 42.27% to -$10.8 million in 2024, then jumped by 40.63% to -$6.4 million in 2025, then soared by 67.42% to -$2.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$2.1 million (Q1 2026), -$6.4 million (Q4 2025), and -$13.8 million (Q3 2025), per Business Quant data.

Peer Comparison